Literature DB >> 9259982

Isolation and nucleotide sequence of canine glucose-6-phosphatase mRNA: identification of mutation in puppies with glycogen storage disease type Ia.

P S Kishnani1, Y Bao, J Y Wu, A E Brix, J L Lin, Y T Chen.   

Abstract

Two Maltese puppies with massive hepatomegaly and failure to thrive had isolated deficient glucose-6-phosphatase (G-6-Pase) activity in liver and kidney and pathological findings compatible with GSD-Ia. To identify the mutation, we cloned G-6-Pase canine cDNA by RT-PCR with primers from the murine G-6-Pase gene sequence. The canine G-6-Pase cDNA is 2346 bp, with a 5' untranslated region of 87 bp, a coding region of 1071 bp, and a 3' untranslated region of 1185 bp. The difference between the canine and human sequences is in the 3' untranslated region. A greater than 90% amino acid sequence homology was seen with canine, human, murine, and rat G-6-Pase. G-6-Pase cDNA from affected and control puppies revealed complete homology except at nt position 450, which showed a guanine to cytosine (G to C) transversion resulting in substitution of a methionine by isoleucine at codon 121 (M121I) in all five clones studied. The loss of an NcoI restriction site on genomic DNA amplified with primers flanking the mutation allowed us to prove that affected puppies were homozygous for the mutation and parents were heterozygous carriers. The mutant G-6-Pase cDNA had 15 times less enzyme activity than wild-type cDNA following transient transfection. Northern blot analysis of puppies with GSD-Ia revealed increased G-6-Pase mRNA, compared to normal controls. Increased G-6-Pase mRNA was also seen in normal fasted puppies compared to littermates in the fed state, suggesting that the increased G-6-Pase mRNA is a physiologic response to fasting. This is the first report of a molecularly confirmed naturally occurring animal model of GSD-Ia. The establishment of a breeding colony of this dog strain will facilitate studies on the role of G-6-Pase gene in glucose homeostasis, in pathophysiology of disease, and development of novel therapeutic approaches such as gene therapy.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9259982     DOI: 10.1006/bmme.1997.2600

Source DB:  PubMed          Journal:  Biochem Mol Med        ISSN: 1077-3150


  18 in total

Review 1.  Mutations in the glucose-6-phosphatase-alpha (G6PC) gene that cause type Ia glycogen storage disease.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Hum Mutat       Date:  2008-07       Impact factor: 4.878

Review 2.  The function of dog models in developing gene therapy strategies for human health.

Authors:  Keri L Nowend; Alison N Starr-Moss; Keith E Murphy
Journal:  Mamm Genome       Date:  2011-07-06       Impact factor: 2.957

3.  Glucose-6-phosphate mediates activation of the carbohydrate responsive binding protein (ChREBP).

Authors:  Ming V Li; Weiqin Chen; Romain N Harmancey; Alli M Nuotio-Antar; Minako Imamura; Pradip Saha; Heinrich Taegtmeyer; Lawrence Chan
Journal:  Biochem Biophys Res Commun       Date:  2010-04-09       Impact factor: 3.575

4.  Recent development and gene therapy for glycogen storage disease type Ia.

Authors:  Janice Y Chou; Goo-Young Kim; Jun-Ho Cho
Journal:  Liver Res       Date:  2017-09

5.  Long-term safety and efficacy of AAV gene therapy in the canine model of glycogen storage disease type Ia.

Authors:  Young Mok Lee; Thomas J Conlon; Andrew Specht; Kirsten E Coleman; Laurie M Brown; Ana M Estrella; Monika Dambska; Kathryn R Dahlberg; David A Weinstein
Journal:  J Inherit Metab Dis       Date:  2018-05-25       Impact factor: 4.982

6.  Pathogenesis of growth failure and partial reversal with gene therapy in murine and canine Glycogen Storage Disease type Ia.

Authors:  Elizabeth Drake Brooks; Dianne Little; Ramamani Arumugam; Baodong Sun; Sarah Curtis; Amanda Demaster; Michael Maranzano; Mark W Jackson; Priya Kishnani; Michael S Freemark; Dwight D Koeberl
Journal:  Mol Genet Metab       Date:  2013-04-06       Impact factor: 4.797

Review 7.  Preclinical Development of New Therapy for Glycogen Storage Diseases.

Authors:  Baodong Sun; Elizabeth D Brooks; Dwight D Koeberl
Journal:  Curr Gene Ther       Date:  2015       Impact factor: 4.391

Review 8.  Gene therapy for type I glycogen storage diseases.

Authors:  Janice Y Chou; Brian C Mansfield
Journal:  Curr Gene Ther       Date:  2007-04       Impact factor: 4.391

Review 9.  Gene therapy for lysosomal storage diseases (LSDs) in large animal models.

Authors:  Mark Haskins
Journal:  ILAR J       Date:  2009

Review 10.  Lessons from new mouse models of glycogen storage disease type 1a in relation to the time course and organ specificity of the disease.

Authors:  Fabienne Rajas; Julie Clar; Amandine Gautier-Stein; Gilles Mithieux
Journal:  J Inherit Metab Dis       Date:  2014-08-28       Impact factor: 4.982

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.